Screener
Corvus Pharmaceuticals CRVS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (161,737) | (7,708) |
| Maturities of marketable securities | 16,982 | 11,987 |
| Purchases of property and equipment | (91) | (36) |
| Net cash (used in) provided by investing activities | (144,846) | 4,243 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in connection with follow-on public offering, net | 189,407 | — |
| Proceeds from exercise of common stock options | 1,339 | 279 |
| Net cash provided by financing activities | 190,746 | 279 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's investing cash flow?
- Corvus Pharmaceuticals (CRVS) reported investing cash flow of -$144.85M in Q1 2026.
- How has Corvus Pharmaceuticals's investing cash flow changed year-over-year?
- Corvus Pharmaceuticals's investing cash flow decreased by 3513.8% year-over-year, from $4.24M to -$144.85M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Corvus Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude